HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).

Abstract
Many patients undergoing moderately or highly emetogenic chemotherapy experience chemotherapy-induced nausea/vomiting (CINV) and report reduced daily functioning, despite prophylaxis with antiemetic drugs. While modern antiemetics have largely alleviated acute emesis, management of nausea and delayed emesis remains particularly challenging. We briefly review the pathophysiologic mechanisms of CINV and the clinical impact of current antiemetics, i.e., the serotonin subtype 3 (5-HT3) receptor antagonists (RAs) and neurokinin-1 (NK1)RAs, before summarizing recent data from clinical trials of new agents. The new antiemetics reviewed include the two most recently approved drugs, the NK1RA rolapitant and the fixed-dose combination product, NEPA, which is composed of the NK1RA netupitant and the 5-HT3RA palonosetron. Phase 3 studies demonstrate improved control of CINV in the delayed and overall phases when rolapitant is added to a standard 5-HT3RA regimen. Phase 2 and phase 3 clinical trials with NEPA demonstrate improved control of CINV in the acute, delayed, and overall phases vs. 5-HT3RA regimens. These data suggest that delayed emesis can be substantially reduced via combined 5-HT3 and NK1 receptor neurotransmitter pathway inhibition.
AuthorsCamilo Rojas, Barbara S Slusher
JournalCancer treatment reviews (Cancer Treat Rev) Vol. 41 Issue 10 Pg. 904-13 (Dec 2015) ISSN: 1532-1967 [Electronic] Netherlands
PMID26442475 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2015 Elsevier Ltd. All rights reserved.
Chemical References
  • Antiemetics
  • Antineoplastic Agents
  • Drug Combinations
  • Isoquinolines
  • Neurokinin-1 Receptor Antagonists
  • Pyridines
  • Quinuclidines
  • Spiro Compounds
  • netupitant, palosentron drug combination
  • rolapitant
Topics
  • Antiemetics (therapeutic use)
  • Antineoplastic Agents (adverse effects)
  • Drug Combinations
  • Humans
  • Isoquinolines (therapeutic use)
  • Nausea (chemically induced, drug therapy)
  • Neurokinin-1 Receptor Antagonists (therapeutic use)
  • Pyridines (therapeutic use)
  • Quinuclidines (therapeutic use)
  • Spiro Compounds (therapeutic use)
  • Vomiting (chemically induced, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: